Epcoritamab for follicular lymphoma not cured by initial treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a drug called epcoritamab for people with follicular lymphoma (a type of slow-growing blood cancer) that improved but did not completely go away after standard first therapy. The goal is to see if epcoritamab can help achieve a complete remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have follicular lymphoma (grades 1-3A) that has CD20 on the surface of the cancer cells.
- You have already received at least 3 cycles of standard first treatment (a CD20 antibody like rituximab plus chemotherapy).
- Your lymphoma got better but did not completely disappear after that first treatment (you had a partial response or stable disease).
- You have measurable disease on a PET/CT scan (at least one lymph node that is visible and active).
- You are age 18 or older, with good organ function and an ECOG performance status of 0-2 (able to care for yourself).
- You have not had any anti-lymphoma therapy for at least 4 weeks before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding epcoritamab, a new immunotherapy drug, to standard chemotherapy (R-CHOP) can help patients with aggressive B-cell lymphomas. The goal is to see if this combination works better than chemotherapy alone.
This phase 2 trial tests whether a combination of epcoritamab plus rituximab can work as a first treatment for follicular lymphoma. It may help people whose lymphoma is causing symptoms or affecting organs, or who have bulky disease, by targeting the lymphoma cells.
This study looks at how well epcoritamab works for people with diffuse large B-cell lymphoma or follicular lymphoma who have already tried two or more treatments. Researchers want to see how it works in routine care, not in a strict research setting.
This trial compares the drug epcoritamab with a 'watch and wait' approach for people with low-tumor-burden follicular lymphoma who have not had treatment before. It tests whether starting treatment early with epcoritamab can improve outcomes.
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
This trial tests adding epcoritamab (an immune therapy that helps your body fight cancer) to standard chemotherapy followed by a stem cell transplant. It is for people with large B-cell lymphoma that has come back or not responded to initial treatment.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.